CYC
CYCLOPHARM LIMITED
$0.4550
▼ -3.19%
Market cap
$57M
Turnover
$49,369
Last price
$0.4550
Day change
-3.19%
Announcements
6
Range, past year
Open 0.580 · Low 0.440 · Now 0.455 · High 1.475
Open CYC in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
CYC momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-10-13.
Momentum quality
31/100
Wyckoff phase
Accumulation5d
Trend stage
Neutral
1 Day
-3.2%
1 Week
-1.1%
1 Month
-15.7%
1 Year
-27.8%
RSI
45
Avg daily range
5.1%
CYCLOPHARM LIMITED scores 31 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.
On the Wyckoff cycle it sits in Accumulation, where it has been for 5 trading days. The weekly timeframe reads Downtrend, which does not yet agree with the daily view.
Against the wider market it is currently matching and the institutional accumulation signal reads low.
Points to watch
- 60d drawdown -26.1%
- Thin liquidity
- Risk rating: Very High
- Composite downside risk elevated
CYC announcements
Recent price-sensitive releases.
- 2026-10-07 Chinese Consensus Names Technegas Preferred Lung Agent Progress Report
- 2026-08-24 Half Yearly Report and Accounts Half Yearly Report | Half Year Audit Review | Half Year Directors' Statement | Half Year Accounts | Half Year Directors' Report
- 2026-08-24 CYC 1H2026 Results Summary Company Presentation | Half Yearly Report
- 2026-07-29 New US Lung Imaging Guidelines Name Technegas as Preferred A Progress Report
- 2026-07-15 Immediate 11-Site Technegas Rollout at University Hospitals
- 2026-07-02 CYC First-Half 2026 Update
More Health Care stocks
Most traded in the same sector.